Clinical Study Shows Vista.ai Significantly Reduces Cardiac MRI Scan Time

Vista.ai, a pioneer and leader in automated MRI solutions, today announced results from a clinical adaptation study on the company’s One Click MRI™ software, led by Dr. Raymond KwongDirector, Cardiac Magnetic Resonance Imaging for Harvard-affiliated Brigham and Women’s Hospital.

The findings show that Vista.ai’s AI-guided image acquisition software improves cardiac MRI (CMR) scan times and achieves high adoption rates by hospital imaging staff. Dr. Kwong will discuss the learnings and implications of the study at an interactive breakfast symposium at 7:20 a.m. PST on Jan. 27, 2023, at the SCMR Scientific Sessions in San Diego.

Dr. Kwong evaluated the use of One Click MRI across approximately 1,100 consecutive studies for cardiomyopathy and structural heart disease, comparing traditional CMR exams against both partial and full AI-assisted scans from April to September 2022.

With respect to CMR exam time, Dr. Kwong’s study found that:

  • Full AI-assisted scans – where a technologist uses One Click MRI to oversee the exam with no manual operation – were 31% shorter than non-AI scans. 

  • 90% of full AI-assisted scans were completed within 45 minutes, while only 25% of unassisted scans were completed within that timeframe.

  • Full AI-assisted scan times were threefold more consistent than unassisted scan times. Both had minimum times of 26 to 27 minutes; however, maximum times were 64 minutes versus 161 minutes, respectively.

Failed adoption of other promising technologies in the medical field has spotlighted the critical importance of gaining support of frontline workers. Notably, Dr. Kwong’s study found that voluntary use of One Click MRI steadily grew as technologists witnessed the software’s ease of use and benefits firsthand. Technologist adoption increased from 13% during the first full month One Click MRI was available (May) to 55% at the end of the study (September).

“An influx of patients with COVID-19-induced cardiac issues further strained the operation of our CMR program at Brigham. Before initiating the One Click MRI study, some outpatients were waiting up to three to four weeks for a CMR scan. Even our sickest inpatients would often have to wait two to five days for a scan,” Dr. Kwong said. “We believe that with continued use of One Click MRI, we will further reduce scan times to an average of 30 minutes, shrink the backlog to improve upon pre-pandemic levels, and sustain a CMR growth rate of about 15% a year.”

A case study summarizing Dr. Kwong’s full clinical findings is available at vista.ai/evidence/studies. In addition to demonstrations of One Click MRI, the case study will also be on display at the Vista.ai’s SCMR booth (#503). 

“A standard CMR is complex and unpredictably long, causing unnecessary stress and burnout for clinicians and discomfort for patients,” said Itamar Kandel, Vista.ai’s CEO. “We applaud Dr. Kwong’s rigorous clinical evaluation of One Click MRI across more than 1,000 patients over a six-month timeframe, and we are thrilled with his conclusions that the software yields positive impacts on clinician workflow, MRI scanner throughput, patient convenience and time to diagnosis. These findings serve as a foundation of evidence to fuel our efforts to make CMR available to all patients who can benefit.”

One Click MRI is initially focused on automating and simplifying a CMR exam, which is increasingly considered the gold-standard cardiac diagnostic, yet is notoriously difficult and time-consuming to complete. Today, specially-trained CMR technologists need to perform the exam, and in the U.S., there is only one such technologist for every 20 MRI machines. Vista.ai recently announced planned expansion beyond the heart to other anatomies and clinical areas.

SourceVista.ai

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”